Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2019 18:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass. and CRESTWOOD, Ky., March 12, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 11, 2019 16:01 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., March 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
March 07, 2019 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass. and CRESTWOOD, Ky., March 07, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
March 06, 2019 16:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., March 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
March 04, 2019 16:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
March 04, 2019 07:00 ET
|
Apellis Pharmaceuticals, Inc.
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM, Mass., March 04, 2019 ...
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
February 28, 2019 10:00 ET
|
Apellis Pharmaceuticals, Inc.
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 17:00 ET
|
Apellis Pharmaceuticals, Inc.
Phase 3 Geographic Atrophy Program Expected to Restart By or In Q2 2019 Phase 3 Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria Expected to be Fully Enrolled by End of Q2 2019 ...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2019 18:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
February 11, 2019 07:00 ET
|
Apellis Pharmaceuticals, Inc.
New designation now includes all PNH patients WALTHAM Mass., and CRESTWOOD, Ky., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical...